Levin Ilan 4
4 · Silexion Therapeutics Corp · Filed Jan 27, 2026
Research Summary
AI-generated summary of this filing
Silexion (SLXN) 10% Owner Ilan Levin Receives 450,000 Shares
What Happened
- Ilan Levin (reported as a 10% owner and related to Moringa Sponsor, LP) is reported to have acquired 450,000 ordinary shares on 2025-09-15 at an effective conversion price of $4.00 per share, a transaction valued at $1,800,000. The filing states these shares were issued to Moringa Sponsor, LP upon conversion of $1.8M of outstanding principal under a convertible promissory note (footnote F4).
- The filing also records earlier pro rata distributions (for no consideration) on 2025-08-07 of 5,550 shares and 935 derivative-related instruments (both shown with $0 consideration) that were distributed by Moringa Sponsor, LP to certain limited partners (footnote F1). The reporting persons note they dispute the validity of the 450,000-share issuance and do not concede beneficial ownership of those shares (footnote F4).
Key Details
- Transaction dates & prices: 2025-09-15 — 450,000 shares at $4.00 each (conversion of $1.8M); 2025-08-07 — pro rata distributions of 5,550 shares and 935 derivative instruments at $0.
- Post-transaction holdings: the filing excerpt does not state a clear total of shares beneficially owned after these transactions; the reporting persons expressly disclaimed (in part) beneficial ownership of the 450,000 shares (F4, F3, F6).
- Footnotes to note: F1 (pro rata distributions), F2/F7 (share and warrant counts adjusted for 1-for-9 and 1-for-15 reverse splits), F3/F6 (ownership structure: Levin controls the general partner entities but disclaims direct beneficial ownership), F4 (conversion issuance disputed).
- Timeliness: Form 4 was filed 2026-01-27 for reportable events in Aug–Sep 2025, indicating a late filing; late filings may draw SEC attention and reduce the usefulness of the timing signal for investors.
Context
- These transactions involve a 10% owner and related sponsor entity, not a routine open-market executive buy or sale. The 450,000-share entry arises from converting debt into equity rather than an outright cash-market purchase — investors should view it as a capital-structure event.
- The reporting persons’ dispute over the issuance (F4) means the filing documents the legal/administrative claim but does not necessarily reflect an uncontested beneficial ownership change.
- Distributions for $0 (gifts/pro rata allocations) and adjustments for reverse splits change reported counts; they are administrative and don’t by themselves signal confidence or lack thereof.
Insider Transaction Report
Form 4
Levin Ilan
Director10% Owner
Transactions
- Other
Ordinary Shares
[F1][F2][F3]2025-08-07−5,550→ 6,970 total(indirect: By Moringa Sponsor, LP.) - Award
Ordinary Shares
[F4][F2][F3]2025-09-15$4.00/sh+450,000$1,800,000→ 456,970 total(indirect: By Moringa Sponsor, LP.) - Other
Warrant (right to buy)
[F7][F1][F3]2025-08-07−935→ 372 total(indirect: By Moringa Sponsor, LP.)Exercise: $1552.50From: 2024-09-14Exp: 2029-08-15→ Ordinary Shares (935 underlying)
Holdings
- 1,482(indirect: By Greenstar, L.P.)
Ordinary Shares
[F5][F2][F6]
Footnotes (7)
- [F1]The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP.
- [F2]The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
- [F3]Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein.
- [F4]The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares.
- [F5]There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- [F6]Moringa Partners Ltd. serves as the sole general partner of Greenstar, L.P. As a result of Ilan Levin being the sole equity owner and serving as the sole director of Moringa Partners Ltd. (as described in footnote (3) above), Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares. The limited partnership interests of Greenstar, L.P. may be held from time to time by various individuals and entities. Mr. Levin disclaims beneficial ownership of the subject ordinary shares except to the extent of his indirect pecuniary interest therein.
- [F7]The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.